BioXcel Therapeutics Inc
Change company Symbol lookup
Select an option...
BTAI BioXcel Therapeutics Inc
BAC Bank of America Corp
CMG Chipotle Mexican Grill Inc
CMCSA Comcast Corp
CLGX Corelogic Inc
CIO City Office REIT Inc
CHKP Check Point Software Technologies Ltd
CHK Chesapeake Energy Corp
CHH Choice Hotels International Inc
CERN Cerner Corp
Go

Health Care : Biotechnology |
Company profile

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company that is focused on the development of drugs for psychiatric disorders and rare cancers. The Company uses novel artificial intelligence (AI) for drug re-innovation processes of approved product candidates to identify new therapeutic indices. Its principal clinical development programs are BXCL501 and BXCL701. BXCL501 is a sublingual thin film formulation of dexmedetomidine (Dex) designed for the acute treatment of agitation resulting from neurological and psychiatric disorders. BXCL701 is an immuno-oncology agent designed for the treatment of prostate and pancreatic cancer.

Closing Price
$36.97
Day's Change
13.12 (55.01%)
Bid
--
Ask
--
B/A Size
--
Day's High
41.59
Day's Low
32.00
Volume
(Heavy Day)
Volume:
4,691,882

10-day average volume:
831,074
4,691,882

Latest Earnings (Q3 ending 09/2019)

Q3
-$0.57
Q3 Consensus estimate
-$0.65

Latest Earnings Estimate Range

Highest
estimate
-$0.56
Mean
estimate
-$0.65
Lowest
estimate
-$0.92

Quarterly Consensus Estimates and Ranges

BTAI's fiscal year ends in December

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Information provided by Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.